Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet the diagnostic criteria for schizophrenia according to DSM-IV-TM for at least 1 year before screening~* have a PANSS score of \<120~* have a body mass index (BMI) \>/=15.0 kilogram (kg)/meter (m)2~* and have resided at the same address for at least 30 days~Exclusion Criteria:~* Patients unable to provide their own consent~* have been involuntarily committed to psychiatric hospitalization~* have primary, active DSM-IV-TM diagnosis other than schizophrenia~* who have a DSM-IV-TM diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)~* have a history of treatment resistance as defined by failure to respond to 2 adequate trials (minimum of 4 weeks at a therapeutic dose) of different antipsychotic medications~* have a history of any severe preexisting gastrointestinal narrowing or inability to swallow the medication whole with water~* have a history of neuroleptic malignant syndrome (NMS)~* are at significant risk of suicidal or violent behavior~* current presence of any significant or unstable medication condition~* treatment with any protocol disallowed therapies~* clinically significant result from screening laboratory or ECG.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
- 002 (Type: PLACEBO_COMPARATOR): Placebo Placebo every 4 wk up to 24 mo

Based on this trial design, predict the completion outcome and termination type (if applicable).